United States (US) Active Pharmaceutical Ingredient (API) Market Overview, 2027

"The United States is home to numerous API (Active Pharmaceutical Ingredient) manufacturers that constantly strive to meet the increasing demand for innovative solutions in the pharmaceutical industry. As the global population grows and ages, there is an increasing demand for medications to treat and manage various diseases and health conditions. The expansion of API production is intimately related to the changing healthcare environment thus creating new opportunities for API manufacturers who can produce high-quality APIs that can help to treat disease. Regulatory authorities, such as the FDA, EMA, and others, set guidelines and standards for APIs' quality, safety, and efficacy. Compliance with these regulations is mandatory for API manufacturers to obtain approvals, and licenses, and ensure patient safety. Changes in regulatory frameworks can influence manufacturing practices and necessitate adaptations in the industry. In the US, manufacturers are exploring the development of APIs that can be customized for individual patients based on their genetic profiles or specific medical needs. This area of research aims to improve treatment efficacy and minimize adverse effects by tailoring therapies to patients' unique characteristics. API manufacturers are adopting continuous manufacturing processes that allow for streamlined production, reduced costs, and improved product quality. Continuous flow reactors and real-time monitoring systems enable more efficient production and better control over critical parameters. Manufacturers are increasingly focusing on environmentally friendly practices by implementing green chemistry principles. This involves using sustainable raw materials, minimizing waste generation, and optimizing chemical processes to reduce environmental impact. According to the report titled ""United States (US) Active Pharmaceutical Ingredients Market Outlook, 2027"" published by Bonafide Research, the market is expected to grow exorbitantly over the forecast period. Though synthetic APIs are widely used to manufacture drugs, biotech APIs are expected to grow rapidly over the forecast period. As the United States aims to reduce reliance on foreign countries, especially for APIs that are critical to public health, and to have the capability to produce them domestically in times of need. The availability of cutting-edge technologies, research facilities, and academic institutions fosters innovation in API manufacturing processes and techniques. API manufacturers in the United States leverage these technological advancements to enhance efficiency, quality, and productivity, contributing to their growth and competitiveness. The captive API segment accounted for the major market share and is expected to grow at a steady CAGR over the forecast period. The manufacturing market in the United States has been experiencing steady growth over the years. The demand for APIs is primarily driven by the increasing need for generic drugs, advancements in drug development, and the rising prevalence of chronic diseases. The United States has one of the largest generic drug markets globally. The manufacturing of API drugs in the United States is distributed across various segments, but the highest manufacturing volume typically occurs in the generic drug segment. Generic APIs are expected to be in demand over the forecast period as the branded API segment's demands are declining. This is due to the consolidation in the pharma industry and various drugs going off-patent. Due to a rise in over-the-counter drugs and the lower cost of generic drugs, it is expected to lure consumers. The increasing obesity, diabetes, and other chronic diseases, which are long-lasting and require the patient to consume the drugs on a daily basis, drive the demand for cheaper alternatives to save costs. Thus, the demand for generic API will rise in future years coupled with government incentives.

The cardiovascular diseases segment accounts for the largest application due to increasing heart-related diseases worldwide. Rising awareness, preventive treatment, and government measures are further expected to drive future demand for API. On the other hand, oncology applications are expected to grow rapidly over the forecast period due to the changing lifestyles of millennials and the growing number of cancer patients in recent years. The metabolic disorders caused by sedentary lifestyles and hormonal imbalances created in the human body are the factors increasing the risks of these diseases. Diabetes is another chronic disease that is on the rise among the populace in the country. The COVID-19 pandemic brought attention to the value of indigenous medication production capacity and supply chain resilience. The pandemic also caused disruptions to the supply chain for APIs. This was due to a number of factors, including factory closures, travel restrictions, and shortages of raw materials. In 2020 the manufacturing of drugs decreased by -2.80% due to supply chain logistics which were at a standstill. However, the future markets are projected to grow exorbitantly as they have recovered from the pandemic shocks. Many manufacturing units in China were shut down due to a lack of raw materials and the pandemic effects which affected the world markets for API. Also, the decrease in demand for pharmaceuticals for certain elective procedures has also led to a decline in the market's growth in 2020. These disruptions made it difficult for API manufacturers to obtain the materials they needed to produce APIs, which led to shortages of some APIs. The US has acknowledged the need to lessen its reliance on foreign suppliers of APIs and essential drugs. Due to this factor, there is now more interest in promoting and funding domestic API production to maintain a steady supply of life-saving medications in the event of catastrophes or breakdowns in the global supply chain. API manufacturers in the United States are pursuing to meet the growing demand for pharmaceutical products. The industry continues to evolve and adapt to advancements in science, technology, and patient needs. API manufacturers are increasingly partnering with research institutions, startups, and other industry stakeholders to foster collaboration and open innovation. By sharing knowledge, resources, and expertise, they can accelerate the development of new ideas and bring innovative products to market more rapidly. API manufacturers are also using new technologies, such as artificial intelligence (AI) and machine learning, to improve their manufacturing processes. These technologies are used to optimize process parameters, predict yields, and identify potential problems. Considered in this report ? Geography: United States (US) ? Historic Year: 2016 ? Base year: 2021 ? Estimated year: 2022 ? Forecast year: 2027

Make this report your own

Have queries/questions regarding a report?

Take advantage of intelligence tailored to your business objective

Ask an Expert

Manmayi Raval

Research Consultant

Aspects covered in this report United States • Active Pharmaceutical Ingredients Market with its value, forecast, and segments • Application wise Active Pharmaceutical Ingredients distribution • Various drivers and challenges • On-going trends and developments • Top profiled companies • Strategic recommendation Based on a synthesis of Active Pharmaceutical Ingredients in the report • Synthetic API • Biotech API Based on the drug type of Active Pharmaceutical Ingredients in the report • Branded API • Generic API

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now

Based on the type of manufacture of Active Pharmaceutical Ingredients in the report • Captive API • Merchant API By Therapeutic Application Type in the report • Communicable Diseases • Oncology • Diabetes • Cardiovascular Disease • Pain management • Respiratory Diseases • Other Therapeutic Applications The approach of the report This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and list out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, annual reports of companies, and analyzing government-generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers in regional aspects, tier aspects, age group, and gender. Once we have primary data with us we have started verifying the details obtained from secondary sources. Intended audience This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to the pharmaceutical industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry. Please get in touch with our sales team to find out more."